← signals
2026-06-27·ASML·prediction market sentiment
lowneutral

Multiple Manifold Markets prediction contracts as of June 27, 2026, provide a snapshot of market beliefs about ASML's...

Multiple Manifold Markets prediction contracts as of June 27, 2026, provide a snapshot of market beliefs about ASML's competitive position.

window 30devidence 9price ASML $1794.62
priced-in check

ASML has not made a large direction-matching 30-90 day move yet.

not priced in
as of 2026-06-267d n/a45d n/a90d +38%yahoo

signal brief

Multiple Manifold Markets prediction contracts as of June 27, 2026, provide a snapshot of market beliefs about ASML's competitive position. The consensus on 'Does China have an ASML EUV machine?' stands at only 16.7% Source 1, indicating low confidence that China has acquired such equipment. Meanwhile, the probability that ASML remains the sole producer of EUV machines through end of 2026 is 79.9% Source 2, and through end of 2027 it is 69.4% Source 4. The market also gives 96.2% odds that ASML was a monopoly in EUV by end of 2024 Source 7. Revenue growth expectations are high: 83.8% chance that ASML's revenue increases every year for the next five years Source 3. On the downside, the probability of China inventing a domestic EUV machine by 2030 is 56.5% Source 6, a near-coin flip that implies material long-term risk. Other contracts, such as CEO criminal charges (11.2%) Source 5 and EUV sales to China in 2023 (6.3%) Source 8, show low concern for near-term legal or export-control shocks. The stock price target of $1,700 in 2024 is given only 1% odds Source 9, suggesting limited upside momentum from current levels. Taken together, these prediction market probabilities indicate a stable but monitored outlook for ASML's monopoly and revenue trajectory, with a notable long-term risk from Chinese domestic EUV development. This constitutes a low-confidence signal as it reflects aggregated sentiment rather than a specific event-driven change.

evidence

spillover entities

Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.